FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2503-2504 June 8, 2006 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In their recent study of the lethal effects of chemotherapy on cancer cells, Casares et al.¹ have shown that, after the fatal blow, cancer cells can take different pathways to death's door, depending on the chemotherapeutic agent used. One of these routes has immunologic consequences with important clinical implications; the other kills the cell without exciting the immune system.¹ The experiments, carried out in mice carrying subcutaneous tumors, indicate that if a chemotherapeutic agent kills cancer cells in a way that renders them immunogenic, it has a therapeutic benefit over and above the cytotoxic action of the drug. The study . . . [Full Text of this Article]

Source Information

From the University of Western Australia, Perth.

This article has been cited by other articles:

• Shurin, G. V., Tourkova, I. L., Kaneno, R., Shurin, M. R. (2009). Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism. J. Immunol. 183: 137-144 [Abstract] [Full Text]  
• de la Cruz-Merino, L., Grande-Pulido, E., Albero-Tamarit, A., Codes-Manuel de Villena, M. E. (2008). Cancer and Immune Response: Old and New Evidence for Future Challenges. The Oncologist 13: 1246-1254 [Abstract] [Full Text]  
• Ladoire, S., Arnould, L., Apetoh, L., Coudert, B., Martin, F., Chauffert, B., Fumoleau, P., Ghiringhelli, F. (2008). Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells. Clin. Cancer Res. 14: 2413-2420 [Abstract] [Full Text]  
• Obeid, M., Panaretakis, T., Tesniere, A., Joza, N., Tufi, R., Apetoh, L., Ghiringhelli, F., Zitvogel, L., Kroemer, G. (2007). Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from "Silent" to Immunogenic. Cancer Res. 67: 7941-7944 [Abstract] [Full Text]  
• Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., Dhodapkar, M. V. (2007). Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109: 4839-4845 [Abstract] [Full Text]